Diagnostics

Liquid biopsy detects circulating tumor DNA, proteins, and exosomes from blood samples. Next-generation sequencing enables comprehensive genomic profiling. AI pathology analyzes tissue slides with accuracy approaching expert pathologists. Multiplex assays measure dozens of biomarkers simultaneously. Point-of-care CRISPR-based diagnostics enable rapid molecular detection.

Liquid biopsy monitors cancer treatment response through serial blood draws rather than repeated imaging. AI pathology detects cancer in tissue samples that human pathologists might miss. Rapid molecular tests diagnose COVID, flu, and strep in 15 minutes at the point of care. Pharmacogenomic testing identifies which drugs will work for individual patients based on their genetic profile.

The global diagnostics market exceeds $80 billion annually, growing at 6-8% CAGR, with the fastest growth in liquid biopsy, point-of-care molecular testing, and AI-powered pathology. With 20 funders in Superscout's database, Diagnostics is a Healthcare child sector that combines medtech capital intensity with high-margin recurring revenue from consumables and test volume.